As it looks ahead to the potential launch of its sustained-delivery treatment Duravyu for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), EyePoint has tapped a new commercial leader with experience heading up ophthalmology franchises at Genentech, Novartis and other drugmakers.
Michael Campbell is taking on the chief commercial officer role at EyePoint, the company announced Wednesday. In his new position, Campbell will take the reins of Duravyu’s launch preparations and commercial strategy.
In a statement, EyePoint CEO Jay Duker, M.D., lauded Campbell’s “proven track record of successfully launching innovative ophthalmology products that revolutionized the retinal disease landscape,” highlighting in particular his work on the launch of Genentech’s Lucentis, “which set the standard in retinal care.”
Campbell spent more than a decade at Genentech starting in 2006, following a string of sales and marketing roles at Eli Lilly and within Johnson & Johnson’s vision care business. At the Roche subsidiary, he played a key role in the launch of Lucentis, the first anti-VEGF treatment approved for wet AMD, including helping to shape its commercial structure, reimbursement strategy, label expansions and more.
In the decade since he left Genentech, Campbell has held a handful of commercial leadership roles, with involvement in eye health products like Shire’s Xiidra—now owned by Bausch + Lomb—as well as Novartis’ Beovu and Viatris’ Tyrvaya. Most recently, he spent a year as CCO of Opthea, helping to lay the commercial groundwork for a wet AMD program that was ultimately scrapped last spring.
EyePoint’s Duravyu drug-device combo is an intravitreal, sustained release insert that delivers the tyrosine kinase inhibitor (TKI) vorolanib.
A phase 3 trial of more than 900 patients is currently underway in wet AMD, with a topline readout expected in mid-2026, and EyePoint has also said it’s planning to begin dosing in a phase 3 trial of Duravyu in DME in the first quarter of this year.
“I am impressed with EyePoint’s de-risked, patient-centric approach to advancing its Phase 3 programs, including thoughtful trial designs that reflect real-world clinical practice and have the potential to support a compelling product label,” Campbell said in this week’s announcement.
“With robust clinical data in both wet AMD and DME, a multi-mechanism of action, and as the only TKI in development for DME, Duravyu offers significant commercial potential and the opportunity to emerge as the next gold standard in retinal disease treatment," he added.